GB0700133D0 - Human cytomegalovirus neutralising antibodies and use thereof - Google Patents

Human cytomegalovirus neutralising antibodies and use thereof

Info

Publication number
GB0700133D0
GB0700133D0 GBGB0700133.2A GB0700133A GB0700133D0 GB 0700133 D0 GB0700133 D0 GB 0700133D0 GB 0700133 A GB0700133 A GB 0700133A GB 0700133 D0 GB0700133 D0 GB 0700133D0
Authority
GB
United Kingdom
Prior art keywords
human cytomegalovirus
neutralising antibodies
cytomegalovirus neutralising
antibodies
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0700133.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Humabs LLC
Original Assignee
Humabs LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37801734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0700133(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Humabs LLC filed Critical Humabs LLC
Priority to GBGB0700133.2A priority Critical patent/GB0700133D0/en
Publication of GB0700133D0 publication Critical patent/GB0700133D0/en
Priority to ES12156048.6T priority patent/ES2526907T3/es
Priority to PT87375903T priority patent/PT2118140E/pt
Priority to RU2009129403/10A priority patent/RU2469045C2/ru
Priority to ES08737590T priority patent/ES2426987T3/es
Priority to PT121560486T priority patent/PT2487187E/pt
Priority to PL08737590T priority patent/PL2118140T3/pl
Priority to US11/969,104 priority patent/US7955599B2/en
Priority to CN2008800071531A priority patent/CN101657467B/zh
Priority to SG2013042486A priority patent/SG191635A1/en
Priority to HRP20130877AT priority patent/HRP20130877T1/hr
Priority to MYPI2013003538A priority patent/MY161200A/en
Priority to KR1020097016334A priority patent/KR101541927B1/ko
Priority to BRPI0806185-8A priority patent/BRPI0806185A2/pt
Priority to CA2673755A priority patent/CA2673755C/en
Priority to MX2009007320A priority patent/MX2009007320A/es
Priority to EP12156048.6A priority patent/EP2487187B1/en
Priority to UAA200908229A priority patent/UA100682C2/ru
Priority to SI200831025T priority patent/SI2118140T1/sl
Priority to JP2009544477A priority patent/JP5710123B2/ja
Priority to PCT/IB2008/001111 priority patent/WO2008084410A2/en
Priority to HK10104864.3A priority patent/HK1139158B/en
Priority to KR1020147021517A priority patent/KR101659306B1/ko
Priority to DK08737590.3T priority patent/DK2118140T3/da
Priority to SG2011097805A priority patent/SG177943A1/en
Priority to MYPI20092825 priority patent/MY150709A/en
Priority to AU2008204258A priority patent/AU2008204258B2/en
Priority to SG2013042544A priority patent/SG192399A1/en
Priority to EP08737590.3A priority patent/EP2118140B1/en
Priority to EP14188865.1A priority patent/EP2860189A3/en
Priority to NZ578844A priority patent/NZ578844A/xx
Priority to US12/174,568 priority patent/US7947274B2/en
Priority to IL199585A priority patent/IL199585A/en
Priority to GT200900188A priority patent/GT200900188A/es
Priority to TNP2009000285A priority patent/TN2009000285A1/fr
Priority to EC2009009547A priority patent/ECSP099547A/es
Priority to CR10961A priority patent/CR10961A/es
Priority to ZA200905408A priority patent/ZA200905408B/xx
Priority to CO09081236A priority patent/CO6220862A2/es
Priority to MA32141A priority patent/MA31225B1/fr
Priority to US13/087,814 priority patent/US8298538B2/en
Priority to US13/092,364 priority patent/US8309089B2/en
Priority to US13/618,264 priority patent/US9217028B2/en
Priority to US13/619,305 priority patent/US8545848B2/en
Priority to HK13101783.4A priority patent/HK1174344B/en
Priority to CY20131100726T priority patent/CY1114271T1/el
Priority to US14/041,799 priority patent/US9149524B2/en
Priority to JP2014043126A priority patent/JP2014141501A/ja
Priority to US14/938,438 priority patent/US9611316B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0700133.2A 2007-01-04 2007-01-04 Human cytomegalovirus neutralising antibodies and use thereof Ceased GB0700133D0 (en)

Priority Applications (49)

Application Number Priority Date Filing Date Title
GBGB0700133.2A GB0700133D0 (en) 2007-01-04 2007-01-04 Human cytomegalovirus neutralising antibodies and use thereof
ES12156048.6T ES2526907T3 (es) 2007-01-04 2008-01-03 Anticuerpos neutralizantes de citomegalovirus humano y su uso
PT87375903T PT2118140E (pt) 2007-01-04 2008-01-03 Anticorpos neutralizantes de citomegalovírus humano e utilização destes
RU2009129403/10A RU2469045C2 (ru) 2007-01-04 2008-01-03 Антитела, нейтрализующие цитомегаловирус человека, и их применение
ES08737590T ES2426987T3 (es) 2007-01-04 2008-01-03 Anticuerpos neutralizantes de citomegalovirus humano y su uso
PT121560486T PT2487187E (pt) 2007-01-04 2008-01-03 Anticorpos neutralizantes de citomegalovírus humano e sua utilização
PL08737590T PL2118140T3 (pl) 2007-01-04 2008-01-03 Przeciwciała neutralizujące ludzki cytomegalowirus i ich zastosowanie
US11/969,104 US7955599B2 (en) 2007-01-04 2008-01-03 Human cytomegalovirus neutralizing antibodies and use thereof
CN2008800071531A CN101657467B (zh) 2007-01-04 2008-01-03 人类巨细胞病毒中和抗体及其用途
SG2013042486A SG191635A1 (en) 2007-01-04 2008-01-03 Human cytomegalovirus neutralising antibodies and use thereof
HRP20130877AT HRP20130877T1 (hr) 2007-01-04 2008-01-03 Antitijela koja neutraliziraju humani citomegalovirus i njihova primjena
MYPI2013003538A MY161200A (en) 2007-01-04 2008-01-03 Human cytomegalovirus neutralising antibodies and use thereof
KR1020097016334A KR101541927B1 (ko) 2007-01-04 2008-01-03 인간 사이토메갈로바이러스 중화 항체 및 이의 용도
BRPI0806185-8A BRPI0806185A2 (pt) 2007-01-04 2008-01-03 anticorpo neutralizador de alta potência, fragmento de um anticorpo, molécula de ácido nucléico, vetor, célula, clone de célula b imortalizado, epìtopo, polipeptìdio imunogênico, método para produção de anticorpos, composição farmacêutica, uso de um primeiro anticorpo ou fragmento, composição ou uso, método para tratamento de um sujeito, kit para diagnóstico de infecção por hcmv, método para preparação de uma célula recombinante, método para produção de anticorpos, método de detecção de polipeptìdios e epìtopo que se liga especificamente a um anticorpo
CA2673755A CA2673755C (en) 2007-01-04 2008-01-03 Human cytomegalovirus neutralising antibodies and use thereof
MX2009007320A MX2009007320A (es) 2007-01-04 2008-01-03 Anticuerpos neutralizantes del citomegalovirus humano y su uso.
EP12156048.6A EP2487187B1 (en) 2007-01-04 2008-01-03 Human cytomegalovirus neutralising antibodies and use thereof
UAA200908229A UA100682C2 (ru) 2007-01-04 2008-01-03 АНТИТЕЛО, КОТОРОЕ НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ ЦИТОМЕГАЛОВИРУС (hCMV), И ЕГО ПРИМЕНЕНИЕ
SI200831025T SI2118140T1 (sl) 2007-01-04 2008-01-03 Protitelesa, ki nevtralizirajo humani citomegalovirus, in njihova uporaba
JP2009544477A JP5710123B2 (ja) 2007-01-04 2008-01-03 ヒトサイトメガロウイルス中和抗体およびその使用
PCT/IB2008/001111 WO2008084410A2 (en) 2007-01-04 2008-01-03 Human cytomegalovirus neutralising antibodies and use thereof
HK10104864.3A HK1139158B (en) 2007-01-04 2008-01-03 Human cytomegalovirus neutralising antibodies and use thereof
KR1020147021517A KR101659306B1 (ko) 2007-01-04 2008-01-03 인간 사이토메갈로바이러스 중화 항체 및 이의 용도
DK08737590.3T DK2118140T3 (da) 2007-01-04 2008-01-03 Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
SG2011097805A SG177943A1 (en) 2007-01-04 2008-01-03 Human cytomegalovirus neutralising antibodies and use thereof
MYPI20092825 MY150709A (en) 2007-01-04 2008-01-03 Human cytomegalovirus neutralising antibodies and use thereof
AU2008204258A AU2008204258B2 (en) 2007-01-04 2008-01-03 Human cytomegalovirus neutralising antibodies and use thereof
SG2013042544A SG192399A1 (en) 2007-01-04 2008-01-03 Human cytomegalovirus neutralising antibodies and use thereof
EP08737590.3A EP2118140B1 (en) 2007-01-04 2008-01-03 Human cytomegalovirus neutralising antibodies and use thereof
EP14188865.1A EP2860189A3 (en) 2007-01-04 2008-01-03 Human cytomegalovirus neutralising antibodies and use thereof
NZ578844A NZ578844A (en) 2007-01-04 2008-01-03 Human cytomegalovirus neutralising antibodies and use thereof
US12/174,568 US7947274B2 (en) 2007-01-04 2008-07-16 Human cytomegalovirus neutralising antibodies and use thereof
IL199585A IL199585A (en) 2007-01-04 2009-06-25 Antibodies that neutralize and utilize human cytomegalovirus
GT200900188A GT200900188A (es) 2007-01-04 2009-07-01 Anticuerpos neutralizantes del citomegalovirus humano y su uso.
TNP2009000285A TN2009000285A1 (en) 2007-01-04 2009-07-03 Human cytomegalovirus neutralising antibodies and use thereof
EC2009009547A ECSP099547A (es) 2007-01-04 2009-07-29 Anticuerpos neutralizantes del citomegalovirus humano y su uso
CR10961A CR10961A (es) 2007-01-04 2009-07-31 Anticuerpos neutralizantes del citomegalovirus humano y su uso
ZA200905408A ZA200905408B (en) 2007-01-04 2009-08-03 Human cytomegalovirus neutralising antibodies and use thereof
CO09081236A CO6220862A2 (es) 2007-01-04 2009-08-04 Anticuerpos neutralizantes de citomegalovirus humano y su uso
MA32141A MA31225B1 (fr) 2007-01-04 2009-08-04 Anticorps neutralisants des cytomegalovirus humains et leur utilisation
US13/087,814 US8298538B2 (en) 2007-01-04 2011-04-15 Human cytomegalovirus neutralising antibodies and use thereof
US13/092,364 US8309089B2 (en) 2007-01-04 2011-04-22 Human cytomegalovirus neutralising antibodies and use thereof
US13/618,264 US9217028B2 (en) 2007-01-04 2012-09-14 Human cytomegalovirus neutralising antibodies and use thereof
US13/619,305 US8545848B2 (en) 2007-01-04 2012-09-14 Human cytomegalovirus neutralising antibodies and use thereof
HK13101783.4A HK1174344B (en) 2007-01-04 2013-02-08 Human cytomegalovirus neutralising antibodies and use thereof
CY20131100726T CY1114271T1 (el) 2007-01-04 2013-08-26 Αντισωματα εξουδετερωσης, ανθρωπινου κυτταρομεγαλοϊου και χρηση αυτων
US14/041,799 US9149524B2 (en) 2007-01-04 2013-09-30 Human cytomegalovirus neutralising antibodies and use thereof
JP2014043126A JP2014141501A (ja) 2007-01-04 2014-03-05 ヒトサイトメガロウイルス中和抗体およびその使用
US14/938,438 US9611316B2 (en) 2007-01-04 2015-11-11 Human cytomegalovirus neutralising antibodies and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0700133.2A GB0700133D0 (en) 2007-01-04 2007-01-04 Human cytomegalovirus neutralising antibodies and use thereof

Publications (1)

Publication Number Publication Date
GB0700133D0 true GB0700133D0 (en) 2007-02-14

Family

ID=37801734

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0700133.2A Ceased GB0700133D0 (en) 2007-01-04 2007-01-04 Human cytomegalovirus neutralising antibodies and use thereof

Country Status (31)

Country Link
US (4) US7955599B2 (enExample)
EP (3) EP2860189A3 (enExample)
JP (2) JP5710123B2 (enExample)
KR (2) KR101541927B1 (enExample)
CN (1) CN101657467B (enExample)
AU (1) AU2008204258B2 (enExample)
BR (1) BRPI0806185A2 (enExample)
CA (1) CA2673755C (enExample)
CO (1) CO6220862A2 (enExample)
CR (1) CR10961A (enExample)
CY (1) CY1114271T1 (enExample)
DK (1) DK2118140T3 (enExample)
EC (1) ECSP099547A (enExample)
ES (2) ES2526907T3 (enExample)
GB (1) GB0700133D0 (enExample)
GT (1) GT200900188A (enExample)
HR (1) HRP20130877T1 (enExample)
IL (1) IL199585A (enExample)
MA (1) MA31225B1 (enExample)
MX (1) MX2009007320A (enExample)
MY (2) MY161200A (enExample)
NZ (1) NZ578844A (enExample)
PL (1) PL2118140T3 (enExample)
PT (2) PT2118140E (enExample)
RU (1) RU2469045C2 (enExample)
SG (3) SG177943A1 (enExample)
SI (1) SI2118140T1 (enExample)
TN (1) TN2009000285A1 (enExample)
UA (1) UA100682C2 (enExample)
WO (1) WO2008084410A2 (enExample)
ZA (1) ZA200905408B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704510B2 (en) * 2006-06-07 2010-04-27 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
US8435510B2 (en) * 2007-08-08 2013-05-07 Sutter West Bay Hospitals Platelet derived growth factor receptor supports cytomegalovirus infectivity
PE20141398A1 (es) 2008-07-16 2014-10-18 Inst Research In Biomedicine Anticuerpos neutralizantes de citomegalovirus humano
AU2008359583B2 (en) * 2008-07-16 2012-04-05 Institute For Research In Biomedicine Human cytomegalovirus neutralising antibodies and use thereof
AU2012203417B2 (en) * 2008-07-16 2014-07-10 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
CA2731686C (en) * 2008-07-25 2020-04-07 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
SI2420572T1 (sl) 2009-04-01 2015-10-30 Evec Incorporated Monoklonsko protitelo, ki je sposobno vezave na specifični diskontinuirani epitop, ki se pojavi pri regiji ad1 glikoproteina gb človeškega citomegalovirusa, in njegov antigen-vezavni fragment
AU2010334809C1 (en) * 2009-12-23 2015-02-26 Agenus Inc. Binding members for human cytomegalovirus
CA2839420C (en) 2010-06-16 2023-06-13 Lawrence M. Kauvar High affinity human antibodies to human cytomegalovirus (cmv) gb protein
HUE044089T2 (hu) 2011-07-18 2019-09-30 Inst Res Biomedicine Neutralizáló anti-influenza A antitestek és alkalmazásaik
HK1206759A1 (en) 2012-03-28 2016-01-15 F. Hoffmann-La Roche Ag Anti-hcmv idiotypic antibodies and uses thereof
WO2014099908A1 (en) * 2012-12-17 2014-06-26 Genentech, Inc. Methods for inhibiting viral infection in transplant patients
SG11201602522VA (en) 2013-10-02 2016-04-28 Medimmune Llc Neutralizing anti-influenza a antibodies and uses thereof
WO2016011035A2 (en) 2014-07-15 2016-01-21 Medlmmune, Llc Neutralizing anti-influenza b antibodies and uses thereof
US20160069643A1 (en) * 2014-09-06 2016-03-10 Philip Lyren Weapon Targeting System
MX389708B (es) 2015-06-01 2025-03-20 Medimmune Llc Neutralizacion de moleculas de union anti-influenza y usos de las mismas.
AU2017205900B2 (en) 2016-01-08 2024-02-15 Kling Biotherapeutics B.V. Therapeutic anti-CD9 antibody
JP2019502715A (ja) 2016-01-13 2019-01-31 メディミューン，エルエルシー Ａ型インフルエンザを治療する方法
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
EP3445393B1 (en) 2016-04-20 2026-01-14 Merck Sharp & Dohme LLC Cmv neutralizing antigen binding proteins
US12037382B2 (en) * 2018-02-05 2024-07-16 Stichting Vu Inverse agonistic anti-US28 antibodies
CN109580944A (zh) * 2018-12-07 2019-04-05 潍坊医学院 一种人巨细胞病毒检测试纸及其制造方法
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN109738631A (zh) * 2019-01-21 2019-05-10 潍坊医学院 一种人巨细胞病毒IgM抗体检测试纸的制备方法
CN118465272B (zh) * 2019-12-04 2025-08-19 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
TWI871709B (zh) 2020-06-21 2025-02-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
WO2022115652A1 (en) * 2020-11-27 2022-06-02 Genentech, Inc. Methods for modulating host cell surface interactions with human cytomegalovirus
CN118580343B (zh) * 2022-10-21 2025-08-19 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1061943A (en) 1964-09-10 1967-03-15 Carter S Ink Co Marking composition
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4294817A (en) 1977-11-25 1981-10-13 International Diagnostic Technology, Inc. Method of fluoro immunoassay
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4313927A (en) 1979-10-19 1982-02-02 Ames-Yissum Ltd. Immunoassay method for detecting viral antibodies in whole blood samples
US4334016A (en) 1980-06-19 1982-06-08 The Wistar Institute Of Anatomy And Biology Human osteogenic sarcoma cell line and use thereof for immunofluorescent antibody test
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
FR2543570B1 (fr) 1983-03-31 1985-08-09 Pasteur Institut Anticorps monoclonaux anticytomegalovirus humains, hybridomes secreteurs de ces anticorps et polypeptides porteurs d'un determinant antigenique sequentiel de cytomegalovirus humains
US4617379A (en) 1983-06-14 1986-10-14 Miles Laboratories, Inc. High titer cytomegalovirus immune serum globulin
GB8404368D0 (en) 1984-02-20 1984-03-28 Cogent Ltd Monoclonal antibodies to human cytomegalovirus
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
FR2563630B1 (fr) 1984-04-27 1988-02-19 Pasteur Institut Anticorps monoclonaux anticytomegalovirus et procedes pour le diagnostic in vitro des infections par les cytomegalovirus humains et d'une proteine-kinase inductible par les cytomegalovirus et susceptible d'etre reconnue par les susdits anticorps monoclonaux
US4783399A (en) 1984-05-04 1988-11-08 Scripps Clinic And Research Foundation Diagnostic system for the detection of cytomegalovirus
US4743562A (en) 1984-08-21 1988-05-10 The Board Of Trustees Of The Leland Stanford Junior University Purified human cytomegalovirus protein
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
EP0198086B1 (en) 1984-09-28 1991-01-16 Teijin Limited Mouse human hybridoma producing antivirus human antibody, process for its preparation, and antivirus human monoclonal antibody
US4808518A (en) 1985-02-11 1989-02-28 University Of Tennessee Research Corporation Recovery of cytomegalovirus antigen and use thereof in an assay
US4804627A (en) 1985-05-09 1989-02-14 Sloan-Kettering Institute For Cancer Research Method for cloning lymphoblastoid cells
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1987003602A1 (fr) * 1985-12-06 1987-06-18 Teijin Limited Anticorps monoclonal humain contre le virus megalocytique et procede de preparation dudit anticorps
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5153311A (en) 1986-11-24 1992-10-06 The Children's Hospital, Incorporated Immunogenic glycoproteins of human cytomegalovirus gCII
US5126130A (en) 1986-11-24 1992-06-30 The Childrens Hospital Incorporated Monoclonal antibodies reactive with specific antigenic sites on human cytomegalovirus glycoprotein a
LU86752A1 (fr) 1987-01-30 1988-08-23 Univ Bruxelles Procede de production d'anticorps monoclonaux humains(igg)anticytomegalovirus et anticorps monoclonaux ainsi obtenus
FI884924A7 (fi) 1987-10-28 1989-04-29 Oncogen Yhdistelmä-DNA-tekniikalla tuotettuja ihmisimmunoglobuliineja
US5180813A (en) 1989-03-24 1993-01-19 University Of Iowa Research Foundation Early envelope glycoprotein of human cytomegalovirus (hmcv) and monoclonal antibodies to the glycoproteins
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
WO1991004277A1 (en) 1989-09-14 1991-04-04 Children's Biomedical Research Institute Monoclonal antibodies specific to cytomegalovirus glycoprotein
WO1991005876A1 (en) 1989-10-20 1991-05-02 Children's Biomedical Research Institute Human cytomegalovirus-specific monoclonal antibody cocktail
GB9008223D0 (en) 1990-04-11 1990-06-13 Royal Free Hosp School Med Improvements relating to the detection of viruses
DE4035174A1 (de) 1990-11-06 1992-05-07 Biotest Ag Verfahren zur bestimmung von proteinen in koerperfluessigkeiten und mittel zur durchfuehrung des verfahrens
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
JPH053794A (ja) * 1991-06-26 1993-01-14 Green Cross Corp:The 抗サイトメガロウイルスヒトモノクローナル抗体およびその産生細胞
DE4128684A1 (de) 1991-08-29 1993-03-04 Behringwerke Ag Hcmv-spezifische peptide, mittel dazu und ihre verwendung
DE69227623T2 (de) 1992-04-10 1999-05-20 Erland Uppsala Hanas Verfahren zum Nachweis einer CMV-Infektion
SE9201281L (sv) 1992-04-23 1993-10-24 Bioinvent Int Ab Nya humana monoklonala antikroppar och förfarande för framställning därav
JPH05260961A (ja) * 1992-05-21 1993-10-12 Teijin Ltd サイトメガロウイルスに対するヒト・モノクローナル抗体を産生するハイブリドーマ
GB9221654D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
EP0680333B1 (en) 1993-01-21 1999-05-06 Erna MÖLLER Prevention and treatment of cytomegalovirus using aminopeptidase
AU695584B2 (en) 1993-01-28 1998-08-20 Novartis Pharmaceutical Corporation Human monoclonal antibodies to cytomegalovirus
US5750106A (en) * 1993-01-28 1998-05-12 Novartis Ag Human monoclonal antibodies to cytomegalovirus
AU6777594A (en) 1993-04-30 1994-11-21 Scripps Research Institute, The Human monoclonal antibodies to human cytomegalovirus, and methods therefor
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
EP0702083A3 (de) 1994-07-26 1997-01-15 Biotest Ag Polypeptide und Fusionsproteine bestehend aus dem UL 57 Leserahmen bzw. dem C-terminalen Bereich des Tegumentproteins pp150 aus HCMV, entsprechende Oligonucleotide und Nachweis reagentien
US5783383A (en) 1995-05-23 1998-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of detecting cytomegalovirus (CMV)
US6019980A (en) 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US5800981A (en) 1996-02-22 1998-09-01 University Of Limburg Human cytomegalovirus antigen and its use
DK0960336T3 (da) 1996-07-12 2003-02-10 Organon Teknika Bv Peptidreagens til påvisning af humant cytomelagovirus (CMV)
CA2263316A1 (en) 1996-08-14 1998-02-19 Klara Berencsi Methods and compositions for preventing or retarding the development of atherosclerotic lesions
EP1003841A4 (en) 1997-01-30 2002-04-17 Cedars Sinai Medical Center CREATION OF A HSV-8 + LYMPHOMATORY CELL LINE, PRODUCT VIRUS, ANTIBODIES, DIAGNOSTIC METHOD AND KIT FOR DETECTING HSV-8 INFECTION
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
WO1998057993A1 (en) 1997-06-19 1998-12-23 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
BR9815496A (pt) 1997-07-18 2001-12-18 Connaught Lab Vacinas de ácido nucléico que codificam proteìna gde vìrus sincicial respiratório
AU749345B2 (en) 1997-11-14 2002-06-27 Connaught Laboratories Limited Alphavirus vectors for paramyxovirus vaccines
DE19756214C1 (de) 1997-12-17 1999-02-25 Biotest Ag Polypeptide mit Aminosäuresequenzen aus dem N-terminalen Bereich von gp116 und deren Verwendung bei der Diagnostik, Prophylaxe und Therapie
ES2186340T3 (es) 1998-03-12 2003-05-01 Genentech Inc Utilizacion de polipeptidos fgf-5 para la prevencion de la muerte de neuronas retinales y para el tratamiento de enfermedades oculares.
DE59907027D1 (de) 1998-06-29 2003-10-23 Wolfgang Bergter Antivirale und antiretrovirale radioimmunpharmaka auf der basis von alpha- und beta-strahlern
RU2133472C1 (ru) 1998-09-16 1999-07-20 Унитарное государственное Московское предприятие по производству бактерийных препаратов Способ диагностики активной стадии цитомегаловирусной инфекции человека
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
ITMI20012160A1 (it) 2001-10-18 2003-04-18 Edoardo Marchisio Sistema immunoenzimatico per la caratterizzazione antigenica dell'infezione attiva da cytomegalovirus e cmv confirmation test
US6828113B2 (en) 2002-03-21 2004-12-07 Cornell Research Foundation, Inc. IgM antibodies to the 70 kDa heat shock protein as a marker for cytomegalovirus infection
CA2480811A1 (en) 2002-04-01 2003-10-16 Agensys, Inc. Nucleic acid and corresponding protein entitled 213p1f11 useful in treatment and detection of cancer
RU2239453C2 (ru) * 2002-12-03 2004-11-10 Федеральное государственное унитарное предприятие " Научно-производственное объединение по медицинским иммунобиологическим препаратам " Микроген" Препарат иммуноглобулина человека против цитомегаловируса и способ его получения
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
WO2004076645A2 (en) 2003-02-27 2004-09-10 University Of Massachusetts Compositions and methods for cytomegalovirus treatment
US20060216302A1 (en) 2003-02-28 2006-09-28 Robert Root-Bernstein Immunological markers
ES2643237T3 (es) 2004-06-21 2017-11-21 E. R. Squibb & Sons, L.L.C. Anticuerpos del receptor 1 de interferón alfa y sus usos
BE1016287A6 (nl) 2004-07-14 2006-07-04 Picanol Nv Gaapvormingsonderdeel voor een weefmachine en weefmachine.
WO2006056027A1 (en) 2004-11-29 2006-06-01 The Council Of The Queensland Institute Of Medical Research Human cytomegalovirus immunotherapy
AU2005333155B2 (en) 2005-03-14 2011-11-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies against Hendra and Nipah viruses
ES2367322T3 (es) 2005-12-16 2011-11-02 Ribovax Biotechnologies Sa Métodos para obtener células inmortalizadas que secretan anticuerpos.
JPWO2007094423A1 (ja) 2006-02-15 2009-07-09 株式会社イーベック ヒトサイトメガロウイルスに結合するヒトのモノクローナル抗体並びにその抗原結合部分
WO2007136778A2 (en) 2006-05-19 2007-11-29 Teva Pharmaceutical Industries, Ltd. Fusion proteins, uses thereof and processes for producing same
US7704510B2 (en) 2006-06-07 2010-04-27 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
EA018701B1 (ru) 2006-12-15 2013-10-30 Рибовакс Байотекнолоджиз Са АНТИТЕЛА К ЦИТОМЕГАЛОВИРУСУ ЧЕЛОВЕКА (hCMV)
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
GB0700133D0 (en) * 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US8361473B2 (en) 2007-03-29 2013-01-29 Technion Research & Development Foundation Ltd. Antibodies and their uses for diagnosis and treatment of cytomegalovirus infection and associated diseases
US20080248042A1 (en) 2007-04-05 2008-10-09 Irccs Centro Di Riferimento Oncologico Di Aviano, Monoclonal antibody cross-reactive against infective agent causing a B-cell expansion and IgG-Fc
WO2009024445A1 (en) 2007-08-22 2009-02-26 Ribovax Biotechnologies Sa Antibodies against human cytomegalovirus (hcmv)
WO2009085383A1 (en) 2007-12-19 2009-07-09 Dcb-Usa Llc Anti-human cytomegalovirus antibodies
AU2008359583B2 (en) 2008-07-16 2012-04-05 Institute For Research In Biomedicine Human cytomegalovirus neutralising antibodies and use thereof
PE20141398A1 (es) 2008-07-16 2014-10-18 Inst Research In Biomedicine Anticuerpos neutralizantes de citomegalovirus humano

Also Published As

Publication number Publication date
US20120076802A1 (en) 2012-03-29
EP2118140B1 (en) 2013-06-19
SG177943A1 (en) 2012-02-28
NZ578844A (en) 2012-08-31
MX2009007320A (es) 2010-02-22
PT2487187E (pt) 2015-02-05
RU2469045C2 (ru) 2012-12-10
CO6220862A2 (es) 2010-11-19
ECSP099547A (es) 2009-11-30
US20140056914A1 (en) 2014-02-27
MY161200A (en) 2017-04-14
AU2008204258B2 (en) 2012-09-06
PL2118140T3 (pl) 2013-11-29
JP5710123B2 (ja) 2015-04-30
HK1174344A1 (en) 2013-06-07
SG191635A1 (en) 2013-07-31
ZA200905408B (en) 2010-05-26
TN2009000285A1 (en) 2010-12-31
KR20140101884A (ko) 2014-08-20
EP2487187A2 (en) 2012-08-15
EP2487187A3 (en) 2012-11-21
EP2118140A2 (en) 2009-11-18
EP2487187B1 (en) 2014-10-22
CY1114271T1 (el) 2016-08-31
WO2008084410A3 (en) 2008-12-24
JP2010516229A (ja) 2010-05-20
ES2526907T3 (es) 2015-01-16
KR101659306B1 (ko) 2016-09-23
AU2008204258A1 (en) 2008-07-17
UA100682C2 (ru) 2013-01-25
EP2860189A2 (en) 2015-04-15
SI2118140T1 (sl) 2013-10-30
KR20090127256A (ko) 2009-12-10
ES2426987T3 (es) 2013-10-28
RU2009129403A (ru) 2011-02-10
SG192399A1 (en) 2013-08-30
CA2673755A1 (en) 2008-07-17
US8309089B2 (en) 2012-11-13
US9149524B2 (en) 2015-10-06
DK2118140T3 (da) 2013-07-01
CA2673755C (en) 2016-04-05
IL199585A (en) 2014-07-31
US20080213265A1 (en) 2008-09-04
EP2860189A3 (en) 2015-07-29
US20130101604A1 (en) 2013-04-25
HK1139158A1 (en) 2010-09-10
BRPI0806185A2 (pt) 2011-08-30
CN101657467B (zh) 2013-11-06
US8545848B2 (en) 2013-10-01
JP2014141501A (ja) 2014-08-07
CN101657467A (zh) 2010-02-24
CR10961A (es) 2009-11-20
GT200900188A (es) 2011-11-29
MY150709A (en) 2014-02-28
KR101541927B1 (ko) 2015-08-05
HRP20130877T1 (hr) 2013-10-25
MA31225B1 (fr) 2010-03-01
US7955599B2 (en) 2011-06-07
PT2118140E (pt) 2013-08-29
WO2008084410A2 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
ZA200905408B (en) Human cytomegalovirus neutralising antibodies and use thereof
ZA201100489B (en) Human cytomegalovirus neutralising antibodies and use thereof
ZA201600335B (en) Human cytomegalovirus neutralizing antibodies and use thereof
ZA201003759B (en) Antibodies against human nkg2d and uses thereof
IL200610A0 (en) Human monoclonal anti-ip-10 antibodies and uses thereof
IL211684A0 (en) Antibodies against human il 17 and uses thereof
ZA201003025B (en) Anti-hepcidin antibodies and uses thereof
IL201034A0 (en) Novel human anti-r7v antibodies and uses thereof
GB0702020D0 (en) Peptides and their use
PT2185719E (pt) Anticorpos anti-rantes e processos para a sua utilização
GB0702021D0 (en) Peptides and their use
IL212795A0 (en) Fully human antibodies against n-cadherin
GB0702022D0 (en) Peptides and their use
IL206334A0 (en) Sarp-i fusion proteins and their use
HRP20190159T1 (hr) Antitijela humanog anti-alfa-sinukleina

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)